semaglutide cause seizures New Study Suggests May Reduce Epilepsy Risk in Type 2 Diabetes Newer glucose‐lowering drugs reduce the

Given Semaglutides proven efficacy in treating conditions associated with metabolic dysfunction and its impact on gastrointestinal physiology, its potential utility in IBS presents a novel area of clinical research

A total of 13,923 subjects were allocated to the semaglutide group and 12,208 individuals were randomised to a control group

Mostly people interested in a tummy tuck

Two initial studies showed a significant difference in retained gastric contents, with there being ~524% retained gastric contents in GLP-1RA users compared to non-users ( In the context of these prior studies, our study adds support for an increase in retained gastric contents for those using GLP-1RA

Given the limited published data on GLP-1 use in GDM, this platform provided the most relevant and up-to-date information, including ongoing studies with detailed protocols not yet available in peer-reviewed literature